Eli Lilly Leads GLP-1 Market on Growth as Novo Nordisk Presents Value Case, Analysis Shows

Eli Lilly is solidifying its leadership in the rapidly expanding GLP-1 drug market with superior growth and a robust pipeline, while rival Novo Nordisk offers a potential value opportunity following a sharp valuation decline, according to a market analysis from Investing.com. Amgen remains a speculative contender as it works to bring its own obesity treatment to market.

Market Dynamics

The global market for obesity drugs, largely driven by the GLP-1 class, is projected to reach approximately $100 billion in annual sales within the next decade. An analysis by Investing.com identifies three distinct investment profiles among the key pharmaceutical players competing for market share: Eli Lilly as the growth leader, Novo Nordisk as a value-based recovery play, and Amgen as a speculative bet on future pipeline success.

Eli Lilly's Premium Growth

Eli Lilly has demonstrated significant operational momentum, posting last-twelve-months revenue growth of 47.4% and a return on invested capital (ROIC) of 45.0%, according to the analysis. The company's pipeline is seen as a key advantage, featuring the recently approved oral GLP-1 drug orforglipron (Foundayo) and retatrutide, a candidate that showed over 28% weight loss in a May 2026 trial.

This performance commands a premium valuation, with the stock trading at 32.0 times forward earnings. While an Investing.com fair value model indicates a potential overvaluation of 6.7%, the analysis notes that Wall Street consensus still sees further upside, reflecting confidence in its multi-year growth runway.

Ad

Novo Nordisk's Contrarian Case

In contrast, Novo Nordisk presents a case for value-oriented investors. The company's stock trades at a more modest 15.6 times forward earnings, and the Investing.com fair value model calculates a potential upside of 37.3%. The company also offers a higher free cash flow yield of 4.2% compared to Lilly's 1.1%.

The lower valuation reflects a significant slowdown in revenue growth to 8.1%, along with previous supply chain issues for its drug Wegovy and what the market perceived as disappointing trial results for its CagriSema candidate. Future performance may hinge on catalysts like its newly approved Wegovy pill and upcoming data for its amycretin drug.

Amgen's Pipeline Bet

Amgen is positioned as the wildcard in the sector, with its investment case centered on its experimental drug, MariTide. The company currently has no approved GLP-1 products but is advancing MariTide through six late-stage trials. According to the analysis, Amgen's ROIC of 16.2% is less than half of its main competitors, reflecting its current status as a challenger rather than an established leader in the space.